About Rani Therapeutics
Rani Therapeutics is a publicly listed company based in San Jose (United States) founded in 2012. Technology for oral delivery of large drug molecules is developed. Rani Therapeutics has raised $226.49 million across 9 funding rounds from investors including Novartis, Astrazeneca and Takeda Pharmaceuticals. The company has 102 employees. Its chief executive, as recorded, is Talat Imran. Rani Therapeutics offers products and services including RaniPill, RT-111, and RT-102. Its focus areas include Life Sciences, Obesity, Drugs and Orthopedics. Its legal entity is Rani Therapeutics, LLC. Its competitors include Aclaris Therapeutics, BioAge Labs and Carmot; 3 of its 3 listed competitors have raised funding.
Company details
Rani Therapeutics was founded in 2012 in San Jose, United States, within the biotechnology sector. A proprietary platform is utilized to enable oral delivery of biologics for chronic disease treatment. The RaniPill capsule is designed for applications in conditions such as acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohns disease, hemophilia, and diabetes. Operations focus on advancing this delivery technology for broader therapeutic use.
- Headquarters San Jose, United States
- Employees 102
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website ranitherapeutics.com
- Social LinkedIn
- Legal Name Rani Therapeutics Holdings, Inc.
- Annual Revenue$1.63 M (USD)58.85as on Dec 31, 2025
- Net Profit-$29.67 M (USD)1.15as on Dec 31, 2025
- EBITDA-$37.41 M (USD)22.98as on Dec 31, 2025
- Total Equity Funding$226.49M (USD)
in 9 rounds
- Latest Funding Round$60.26M (USD), Post-IPO
Oct 2025
- InvestorsNovartis
& 18 more
- Employee Count102
Products & Services of Rani Therapeutics
Rani Therapeutics offers a comprehensive portfolio of products and services, including RaniPill, RT-111, and RT-102.
Capsule for oral administration of biologics to improve patient compliance.
Platform for oral ustekinumab delivery in clinical trials.
System for repeated oral biologic dosing in therapeutic applications.
Funding Insights of Rani Therapeutics
Rani Therapeutics has successfully raised a total of $226.49M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $60.26 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $226.49M
- Total Rounds 9
- Last Round Post-IPO — $60.26M
- Investors Count 19
All 9 funding rounds of Rani Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $60.26M | Post-IPO | – | – | – |
| Dec 2020 | $69M | Series E | – | – | – |
| Nov 2020 | $50M | Series E | – | – | – |
| Feb 2018 | $53M | Series E | – | GeneScience Pharmaceuticals, Shire | |
| Sep 2017 | $39M | Series D | – | – | |
| Feb 2016 | Series D | – | – | ||
| May 2015 | $15.49M | Series C | – | – | |
| May 2015 | $7.65M | Series C | – | – | – |
| Aug 2013 | Series B | – | – |
19 investors in total: 19 institutional.
Investors in Rani Therapeutics
Rani Therapeutics has secured backing from 19 investors, including institutional and venture fund investors. Prominent investors backing the company include Novartis, Astrazeneca and Takeda Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Corporate backed venture capital fund investing in multiple sectors | gv.com | Mountain View, United States | ||
Corporate-backed venture capital firm focused on retail tech, mobile tech, and multiple sectors | pinganventures.com | Pudong, China | ||
Cathay Capital is engaged in global investment and transformation. | cathaycapital.com | Paris, France | ||
| vi-ventures.com | ||||
Healthcare startups are supported through venture capital investments. | incubevc.com | San Jose, United States | ||
Healthcare sector investments are managed by VentureHealth venture capital fund. | venturehealth.com | San Jose, United States | ||
Global innovation is invested in across public and private markets. | alphasquaregroup.com | New York, United States | ||
Corporate backed venture capital firm investing in life sciences sector | nanfunglifesciences.com | San Francisco, United States | ||
Development of the angel investment community is promoted through networking. | bansea.org | Singapore, Singapore | ||
| tzjf.com.cn |
Investor details for Rani Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rani Therapeutics
37 people are tracked at Rani Therapeutics (11 in leadership, 6 in board & advisors, 20 in team); the tracked headcount is 102.
| Name | Role | Group |
|---|---|---|
Talat Imran | CEO | Leadership |
Bella Vazquez | VP, Human Resources | Leadership |
Arvinder Dhalla | VP, Clinical Development | Leadership |
Kate Flavin McKinley | Chief Business Officer | Leadership |
Baber Syed | Director, Research and Development (Robotic Pill) | Leadership |
Previn Brito | Senior Director, Financial Planning & Analysis and Strategic Initiatives | Leadership |
Ali Javadi | Senior Director of Operations | Leadership |
Jacques Van Dam | VP, Medical Affairs | Leadership |
Svai Sanford | Chief Financial Officer | Leadership |
Mir Hashim | Chief Scientific Officer | Leadership |
Kate McKinley | Chief Business Officer | Leadership |
Dennis Ausiello | Director | Board & advisors |
Maulik Nanavaty | Director | Board & advisors |
Andrew Farquharson | Director | Board & advisors |
Jean-Luc Butel | Board Member. Chair Nominating And Corporate Governance Committee | Board & advisors |
Mir Imran | Executive Chairman | Board & advisors |
Lisa Rometty | Director | Board & advisors |
Mary Hoopes | Senior Strategic Analyst | Team |
Anusha Garapaty, PhD | Scientist IV | Team |
Kushagra Varshneya | Mechanical Engineer III | Team |
17 more people are available in the full profile.
Complete people profiles for Rani Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Rani Therapeutics
Rani Therapeutics is a publicly listed company on the NASDAQ with ticker symbol RANI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date30 Jul 2021
- Listed onNASDAQ: RANI
- Listed entityRani Therapeutics Holdings, Inc.
- Exchange sectorHealth technology
- ISINUS7530181004
- Share price$0.73 (-2.36% on the day) · 2026-10-13
- Market capitalisation$102.2M
- EPS (diluted, trailing year)$-0.27
- Volume (last session)918,670
Financials of Rani Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $1.6M | -$29.7M | -$37.4M |
| 2024 | $1.0M | -$30.0M | -$48.6M |
| 2023 | -$34.0M | -$65.3M | |
| 2022 | -$30.6M | -$62.1M | |
| 2021 | $2.7M | -$8.3M | -$51.1M |
Detailed financial statements for Rani Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Rani Therapeutics
4 dated milestones of Rani Therapeutics across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Rani Therapeutics is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $60.3M.
Competitors of Rani Therapeutics
Rani Therapeutics has 3 listed competitors in our database, 3 of them funded. They include Aclaris Therapeutics, BioAge Labs and Carmot.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aclaristx.com | 2012 | Malvern, United States | $82M | 180 | Novel dermatologic therapies are developed for skin conditions. | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | Disease-modifying therapies for metabolic diseases are developed. |
Detailed competitors of Rani Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Rani Therapeutics
The website of Rani Therapeutics (ranitherapeutics.com) receives about 8.8K visits a month and ranks #2,340,874 among all websites worldwide, #3,194 in Biotechnology and Pharmaceuticals.
- Monthly visits8.8K
▼ 8.3% vs previous month
- Unique visitors3.9K
per month
- Global rank#2,340,874
among all websites
- Category rank#3,194
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.7
- Average visit22 sec
- DevicesDesktop 41% · Mobile 59%
Websites whose visitors overlap most with Rani Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| pharmaceutical-technology.com | 100% | #316,052 | View details |
Top companies in Orthopedics
3 companies that operate in the same segment as Rani Therapeutics (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rani Therapeutics
Complete news archive for Rani Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rani Therapeutics
Rani Therapeutics was founded in 2012 and raised its 1st funding round 1 year after it was founded.
Rani Therapeutics is headquartered in San Jose, United States. It is registered at San Jose, California, United States.
Talat Imran is the CEO of Rani Therapeutics, as recorded in our data.
Rani Therapeutics is a funded company, having raised a total of $226.49M across 9 funding rounds to date.
Rani Therapeutics has 102 employees.
Annual revenue of Rani Therapeutics is $1.63M as on Dec 31, 2025.
Rani Therapeutics was founded in 2012 in San Jose, United States, within the biotechnology sector. A proprietary platform is utilized to enable oral delivery of biologics for chronic disease treatment. The RaniPill capsule is designed for applications in conditions such as acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohns disease, hemophilia, and diabetes. Operations focus on advancing this delivery technology for broader therapeutic use.
Rani Therapeutics's top competitors include BioAge Labs, Aclaris Therapeutics and Carmot.
Rani Therapeutics offers RaniPill, RT-111, and RT-102.
Yes, Rani Therapeutics is publicly traded on NASDAQ under the ticker symbol RANI.
Rani Therapeutics has 19 investors. Key investors include Novartis, Astrazeneca, Takeda Pharmaceuticals, Cathay Financial Holdings, and Stevanato Group.
Rani Therapeutics operates through Rani Therapeutics, Llc.